Kuvan
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Phenylketonuria (PKU)
Conditions
Phenylketonuria (PKU)
Trial Timeline
May 1, 2012 → Dec 1, 2014
NCT ID
NCT01617070About Kuvan
Kuvan is a approved stage product being developed by BioMarin Pharmaceutical for Phenylketonuria (PKU). The current trial status is completed. This product is registered under clinical trial identifier NCT01617070. Target conditions include Phenylketonuria (PKU).
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03864029 | Pre-clinical | Completed |
| NCT02353312 | Pre-clinical | Completed |
| NCT01806051 | Pre-clinical | Terminated |
| NCT01617070 | Approved | Completed |
| NCT00827762 | Pre-clinical | Terminated |
| NCT00778206 | Pre-clinical | Completed |
Competing Products
20 competing products in Phenylketonuria (PKU)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SYNB1934v1 + Placebo | Synlogic | Phase 3 | 69 |
| SYNB1618 + Placebo | Synlogic | Phase 1/2 | 33 |
| SYNB1618 + SYNB1934 | Synlogic | Phase 2 | 44 |
| Kuvan® | Merck | Phase 3 | 77 |
| Kuvan® | Merck | Approved | 85 |
| SAR444836 | Sanofi | Phase 1/2 | 40 |
| Kuvan | BioMarin Pharmaceutical | Pre-clinical | 20 |
| rAvPAL-PEG | BioMarin Pharmaceutical | Phase 2 | 49 |
| rAvPAL-PEG | BioMarin Pharmaceutical | Phase 2 | 49 |
| Sapropterin (Kuvan) | BioMarin Pharmaceutical | Pre-clinical | 20 |
| BMN 165 (rAvPAL-PEG) | BioMarin Pharmaceutical | Phase 2 | 49 |
| BMN 307 | BioMarin Pharmaceutical | Phase 1/2 | 38 |
| Sapropterin | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Sapropterin dihydrochloride + Placebo | BioMarin Pharmaceutical | Phase 3 | 74 |
| BMN165 20mg/day + BMN165 40mg/day + Placebo | BioMarin Pharmaceutical | Phase 3 | 74 |
| sapropterin dihydrochloride | BioMarin Pharmaceutical | Phase 3 | 74 |
| saproterin dihydrochloride | BioMarin Pharmaceutical | Approved | 82 |
| sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placebo | BioMarin Pharmaceutical | Phase 1 | 30 |
| Pegvaliase | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Pegvaliase | BioMarin Pharmaceutical | Pre-clinical | 20 |